
Ora Pharm calls out NUBU over false Helius discontinuation claim
Ora Pharm put out a media release yesterday confirming that Helius products remain available following its acquisition of the business and key assets.
The release responds to a 9 July newsletter from MW Pharma Limited, trading as NUBU, which said: "Helius Therapeutics has ceased production, and all products are now discontinued".
Ora Pharm says that was incorrect.
According to the release, Ora Pharm completed the acquisition on 18 June 2026, with manufacturing, packaging and nationwide distribution resuming the following day. Helius branded formulated products and locally grown products remain approved and available for patients.
The NUBU communication was reportedly sent to clinics, GPs and others in the sector, and included guidance on switching patients away from Helius products to NUBU alternatives. That makes it even harder to swallow when NUBU’s own range is made up almost entirely of imported products, while Helius has actually put in the work, investment and regulatory effort required to manufacture medicinal cannabis products here in New Zealand.
When it was first announced that Helius was going, before Ora Pharm stepped in, there was a lot of uncertainty among patients here on Reddit. Many people were genuinely worried they were about to lose access to medicines that were working for them. For anyone who has already spent time and money finding the right product and dose, that kind of uncertainty is incredibly stressful!
It also has real consequences. Doctors may change prescriptions, pharmacies may give patients the wrong information, and people can end up being moved onto products that do not work the same for them.
Ora Pharm says the statement caused unnecessary uncertainty for patients, prescribers and pharmacies, and risked disrupting treatment decisions. So for anyone who was told Helius products were gone, Ora Pharm says that is not the case. Production and distribution are operating, and Helius products remain available.
Patients who have been told otherwise should check directly with their pharmacy or prescriber before changing treatment based on misinformation circulated by NUBU.
NBR has also reported on Ora Pharm seeking an injunction in the dispute with NUBU. The article is paywalled: https://www.nbr.co.nz/primary-industries/injunction-sought-in-row-between-medicinal-cannabis-firms